德克萨米他的使用暂时增加马的胰岛素对口服碳水化合物挑战的反应
François-René Bertin1, Andrew W van Eps2, Demia J de Tonnerre3
1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West-Lafayette, IN.
American journal of veterinary research
|February 12, 2025
概括
在口服葡萄糖挑战后,甲在马中暂时增加了胰岛素分泌和脂质调动,作用在第15天减弱. 这表明,尽管持续存在胰岛素耐药性,但对岛内内轴有暂时的影响.
科学领域:
- 兽医内分泌学 兽医内分泌学
- 马类的新陈代谢
- 药理学 药理学是指药理学的学科.
背景情况:
- 德克萨米他是一种用于诱导实验性胰岛素抵抗的皮质类固醇.
- 它对马的胰岛素分泌的确切影响尚不完全理解.
- 研究这些影响对于理解马类代谢健康至关重要.
研究的目的:
- 评估德克萨米他对马匹胰岛素分泌和相关代谢参数的影响.
- 为了评估马匹在德克萨梅他治疗期间对口服碳水化合物挑战的反应.
主要方法:
- 在14天的时间里,八匹健康的标准品种马接受了德克萨米他的治疗.
- 口服葡萄糖耐受性测试 (OGT) 在第1,第8和第15天进行.
- 测量包括葡萄糖,胰岛素,甘油三,总和活性葡萄糖类-1 (tGLP-1和aGLP-1),以及依赖葡萄糖的胰岛素型多 (GIP).
主要成果:
- 8天后,德克萨米他显著增加了葡萄糖,胰岛素,甘油三,tGLP-1和OGT后GIP曲线下的面积 (AUC).
- 到第15天,这些增加已经减弱,葡萄糖,胰岛素和aGLP-1 AUC明显低于第8天.
- 没有一匹马出现临床层状炎.
结论:
- 德克萨米他暂时增强胰岛素分泌,脂质调动,并在口服葡萄糖挑战后刺激马的肠岛轴.
- 这些代谢效应在治疗的第15天似乎部分可逆.
- 虽然德克萨米他始终诱导胰岛素抵抗,但其对胰岛素分泌的影响是暂时的.
相关概念视频
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Insulin: Dosing Regimen and Adverse Effects
140
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
140
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Glucose Homeostasis: Regulation of Blood Glucose
1.4K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.4K


